Cargando…
Tofacitinib Treatment in Patients With Active COVID-19 Infection
Alopecia areata is a chronic autoimmune disorder attacking the hair follicle epithelium; hence, causing non-scarring hair loss. It has been found that Janus kinase 3 (JAK3) hyperactivity plays a key role in the pathogenesis of the disease. Tofacitinib is an effective JAK1 and JAK3 inhibitor that can...
Autores principales: | Alajlan, Abdulmajeed M, AlZamil, Lama R, Aseri, Amal M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516018/ https://www.ncbi.nlm.nih.gov/pubmed/34660145 http://dx.doi.org/10.7759/cureus.17957 |
Ejemplares similares
-
Dapsone in the Management of Pemphigus and Pemphigoid: Rediscovery of its Long-Lost Efficacy
por: Alkeraye, Salim, et al.
Publicado: (2020) -
Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021) -
Oral Tofacitinib Therapy for the Effective Management of Netherton Syndrome
por: Dodeja, Ajay, et al.
Publicado: (2023) -
Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study
por: Alsuhibani, Abdulaziz S, et al.
Publicado: (2023) -
Atypical Presentation of Herpes Simplex Virus Infection in an Immunocompromised Patient
por: Alghamdi, Nada, et al.
Publicado: (2023)